MA40030A - Conjugués peptide-médicament - Google Patents
Conjugués peptide-médicamentInfo
- Publication number
- MA40030A MA40030A MA040030A MA40030A MA40030A MA 40030 A MA40030 A MA 40030A MA 040030 A MA040030 A MA 040030A MA 40030 A MA40030 A MA 40030A MA 40030 A MA40030 A MA 40030A
- Authority
- MA
- Morocco
- Prior art keywords
- peptide
- drug conjugates
- linker
- self
- drug
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 4
- 229940127089 cytotoxic agent Drugs 0.000 abstract 3
- 239000002254 cytotoxic agent Substances 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- HZQYAEDFCYEQMF-UHFFFAOYSA-N (4-aminophenyl) hydrogen carbonate Chemical compound NC1=CC=C(OC(O)=O)C=C1 HZQYAEDFCYEQMF-UHFFFAOYSA-N 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- -1 p-aminobenzyl carbamoyl Chemical group 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462007159P | 2014-06-03 | 2014-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40030A true MA40030A (fr) | 2015-12-10 |
Family
ID=54700553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040030A MA40030A (fr) | 2014-06-03 | 2015-06-01 | Conjugués peptide-médicament |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9579317B2 (enExample) |
| EP (1) | EP3152223B1 (enExample) |
| JP (2) | JP6539729B2 (enExample) |
| CN (1) | CN106456799B (enExample) |
| AU (1) | AU2015270924B2 (enExample) |
| CA (1) | CA2951049C (enExample) |
| ES (1) | ES2857192T3 (enExample) |
| MA (1) | MA40030A (enExample) |
| WO (1) | WO2015187540A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3184540A4 (en) * | 2014-08-22 | 2018-03-21 | Yafei Shanghai Biolog Medicine Science& Technology | Specifically activated micromolecular target coupling body in tumor microenvironment and use thereof |
| JP7251981B2 (ja) | 2016-03-24 | 2023-04-04 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
| CN107375288B (zh) * | 2016-05-16 | 2019-08-23 | 博瑞生物医药（苏州）股份有限公司 | 多臂的聚合靶向抗癌偶联物 |
| EP3558386A1 (de) | 2016-12-21 | 2019-10-30 | Bayer Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
| CN108314703B (zh) * | 2017-01-17 | 2022-02-01 | 亚飞（上海）生物医药科技有限公司 | 分子定点靶向和激活的激酶抑制剂的制备和用途 |
| JP6947909B2 (ja) | 2017-04-21 | 2021-10-13 | 博瑞生物医薬（蘇州）股▲分▼有限公司Ｂｒｉｇｈｔｇｅｎｅ Ｂｉｏ−Ｍｅｄｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． | マルチアーム標的抗がんコンジュゲート |
| CN107670048B (zh) * | 2017-08-30 | 2019-04-26 | 南京明臻医药科技有限公司 | 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用 |
| CA3125552A1 (en) * | 2019-01-07 | 2020-07-16 | Cenna Biosciences Inc. | Novel peptides and uses thereof |
| CN114286693A (zh) * | 2019-04-05 | 2022-04-05 | 普罗林科斯有限责任公司 | 改良偶联接头 |
| US20220313625A1 (en) * | 2019-05-24 | 2022-10-06 | The Jikei University | Pharmaceutical agent, medicinal solution for cleaning pulmonary alveoli, and nebulizer |
| KR20230141754A (ko) * | 2020-10-30 | 2023-10-10 | 아박타 라이프 사이언시스 리미티드 | Fap-활성화 혈청 반감기 연장된 치료 접합체 |
| JP2023548136A (ja) * | 2020-10-30 | 2023-11-15 | アバクタ・ライフ・サイエンシーズ・リミテッド | 酵素活性化血清半減期延長型治療用コンジュゲート |
| CN115850288B (zh) * | 2022-11-25 | 2025-03-21 | 中科帅天医药(深圳)有限公司 | 一种丝裂霉素c前体药物及其制备方法和应用 |
| CN120835795A (zh) * | 2023-03-09 | 2025-10-24 | 拜斯科技术开发有限公司 | 双环毒素偶联物及其中间体的合成 |
| CN117683079B (zh) * | 2023-12-12 | 2025-04-04 | 九洲药业(杭州)有限公司 | 一种抗体偶联药物连接子的固相合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3803223A (en) * | 1970-07-20 | 1974-04-09 | Searle & Co | 3-amino-n-substituted succinamic acids and intermediates thereto |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| KR20020082227A (ko) * | 2000-02-24 | 2002-10-30 | 제넨테크, 인크. | 카스파제 활성화 전구약물 요법 |
| US8314060B2 (en) | 2000-09-05 | 2012-11-20 | Biosight Ltd. | Peptide conjugated anti-cancer prodrugs |
| CA2536357A1 (en) * | 2003-05-29 | 2004-12-23 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
| EP1976861A2 (en) | 2005-11-29 | 2008-10-08 | The Scripps Research Institute | Inhibiting tumour cell invasion, metastasis and angiogenesis through targetting legumain |
| EP2266964B1 (en) * | 2009-06-22 | 2013-01-09 | KTB Tumorforschungsgesellschaft mbH | Acid-labile trigger units |
| US8394922B2 (en) * | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| WO2012075472A2 (en) | 2010-12-03 | 2012-06-07 | Regents Of The University Of Colorado, A Body Corporate | Chemical entities and therapeutic uses thereof |
-
2015
- 2015-06-01 CA CA2951049A patent/CA2951049C/en active Active
- 2015-06-01 AU AU2015270924A patent/AU2015270924B2/en active Active
- 2015-06-01 ES ES15803150T patent/ES2857192T3/es active Active
- 2015-06-01 WO PCT/US2015/033509 patent/WO2015187540A1/en not_active Ceased
- 2015-06-01 JP JP2017516251A patent/JP6539729B2/ja active Active
- 2015-06-01 EP EP15803150.0A patent/EP3152223B1/en active Active
- 2015-06-01 CN CN201580029854.5A patent/CN106456799B/zh active Active
- 2015-06-01 US US14/726,897 patent/US9579317B2/en active Active
- 2015-06-01 MA MA040030A patent/MA40030A/fr unknown
-
2017
- 2017-01-27 US US15/417,615 patent/US20170232023A1/en not_active Abandoned
-
2019
- 2019-06-10 JP JP2019107602A patent/JP2019189623A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015270924B2 (en) | 2019-09-12 |
| JP2019189623A (ja) | 2019-10-31 |
| US9579317B2 (en) | 2017-02-28 |
| CA2951049A1 (en) | 2015-12-10 |
| JP6539729B2 (ja) | 2019-07-03 |
| CN106456799B (zh) | 2020-05-22 |
| EP3152223A1 (en) | 2017-04-12 |
| JP2017521486A (ja) | 2017-08-03 |
| CN106456799A (zh) | 2017-02-22 |
| US20170232023A1 (en) | 2017-08-17 |
| WO2015187540A1 (en) | 2015-12-10 |
| US20150343083A1 (en) | 2015-12-03 |
| EP3152223A4 (en) | 2017-12-20 |
| EP3152223B1 (en) | 2020-11-25 |
| CA2951049C (en) | 2023-01-03 |
| AU2015270924A1 (en) | 2016-12-15 |
| ES2857192T3 (es) | 2021-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40030A (fr) | Conjugués peptide-médicament | |
| NZ720743A (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
| PH12018500693A1 (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
| CY1123675T1 (el) | Πολυαιθυλενογλυκολιωμενου φαρμακου-συνδετες για βελτιωμενες φαρμακοκινητικες προϊοντος συζευξης προσδετη-φαρμακου | |
| ZA201903667B (en) | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers | |
| PH12016501995A1 (en) | Tubulysin derivatives | |
| MX2021008334A (es) | Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco. | |
| AR088694A1 (es) | Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos | |
| CL2016001514A1 (es) | Conjugado de anticuerpo-farmaco que posee un resto quimico no peptidico, que puede ser escindido por la catepsina b; uso para la fabricacion de un medicamento util y conjugacion farmaceutica. | |
| PH12016500246A1 (en) | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment | |
| MX2021010550A (es) | Conjugados de anticuerpo-farmaco hidrofilicos. | |
| NZ754810A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| WO2014062697A3 (en) | Drug delivery conjugates containing unnatural amino acids and methods for using | |
| MX2018010247A (es) | Nuevos conjugados de amanitina. | |
| HK1222122A1 (zh) | 选择性药物递送组合物及使用方法 | |
| MX2013003452A (es) | Conjugados de amatoxina con enlazantes mejorados. | |
| PH12015501422B1 (en) | Hydrophilic self-immolative linkers and conjugates thereof | |
| IN2015DN02577A (enExample) | ||
| MY169147A (en) | Drug-protein conjugates | |
| MX344009B (es) | Conjugados de amatoxinas con enlaces mejorados. | |
| MX2015011583A (es) | Derivados de amatoxina. | |
| MX2021005134A (es) | Nuevos conjugados citostaticos con ligandos de integrina. | |
| MX2016007578A (es) | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento. | |
| AR095072A1 (es) | Conjugados antibióticos | |
| EA202091203A1 (ru) | Конъюгаты лиганда-лекарственного средства в качестве субстратов для селективного расщепления под действием экзопептидазной активности катепсина b |